(Q44144430)

30 November 2017

title

Bioavailability of lansoprazole granules administered in juice or soft food compared with the intact capsule formulation (English)

1 reference

30 November 2017

1 reference

Alexander H C Chun

1

1 reference

30 November 2017

Keith Erdman

2

1 reference

30 November 2017

Yi-Lin Chiu

3

1 reference

30 November 2017

Betsy L Pilmer

4

1 reference

30 November 2017

Ramanuj Achari

5

1 reference

30 November 2017

John H Cavanaugh

6

1 reference

30 November 2017

language of work or name

1 reference

1 August 2002

1 reference

30 November 2017

published in

Clinical Therapeutics

1 reference

30 November 2017

volume

24

1 reference

30 November 2017

issue

8

1 reference

30 November 2017

page(s)

1322-1331

1 reference

Acid suppression in duodenal ulcer: a meta-analysis to define optimal dosing with antisecretory drugs

30 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980036-4

7 January 2021

Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980036-4

7 January 2021

Appropriate acid suppression for the management of gastro-oesophageal reflux disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980036-4

7 January 2021

Time to maximum effect of lansoprazole on gastric pH in normal male volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980036-4

7 January 2021

Lansoprazole: an alternative method of administration of a capsule dosage formulation

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980036-4

7 January 2021

Lansoprazole: administration of the contents of a capsule dosage formulation through a nasogastric tube

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980036-4

7 January 2021

Effect on bioavailability of admixing the contents of lansoprazole capsules with selected soft foods

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980036-4

7 January 2021

The pharmacodynamics of lansoprazole administered via gastrostomy as intact, non-encapsulated granules

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980036-4

7 January 2021

Comparison of 24-hour intragastric pH using four liquid formulations of lansoprazole and omeprazole.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980036-4

7 January 2021

A comparison of the Two One-Sided Tests Procedure and the Power Approach for assessing the equivalence of average bioavailability

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980036-4

7 January 2021

A prospective study of simplified omeprazole suspension for the prophylaxis of stress-related mucosal damage.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980036-4

7 January 2021

A prospective study of omeprazole suspension to prevent clinically significant gastrointestinal bleeding from stress ulcers in mechanically ventilated trauma patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980036-4

7 January 2021

Efficacy and safety of omeprazole for severe gastroesophageal reflux in children.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980036-4

7 January 2021

Importance of pH control in the management of GERD.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980036-4

7 January 2021

10.1016/S0149-2918(02)80036-4

Identifiers

DOI

1 reference

30 November 2017

1 reference